Dr Michael Levy (Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA) provides his highlights from the 75th AAN Annual Meeting, 2023, in particular that this was the first year to have a myelin oligodendrocyte glycoprotein (MOG) antibody disease focus, with posters on two phase 3 trials, which are expected to be presented in 2026.
Disclosures: Michael Levy is a consultant for, and has received grant/research support from Alexion, Horizon, Genentech, Aeterna Zentaris, UCB and Sanofi. He is also a member of the Advisory Board for Alexion, Horizon, Genentech, UCB and Sanofi.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed as a highlight of the 75th AAN Annual Meeting, 2023
Access more content on neuroimmunology here
Transcript
My name is Michael Levy, I’m an associate professor of neurology at Massachusetts General Hospital in Harvard Medical School. This is the first year that they had a MOG-specific section. This is MOG antibody disease, a close relative of NMO, in which immunity to MOG causes optic neuritis and transverse myelitis. There are two phase-three international clinical trials that have launched in this space, and there were poster sessions and talks on protocol design and ethics and readouts of those two trials, which are expected to be in 2026. And so, that’s exciting in the area. And similarly, in the autoimmune space, we have trials now that have launched in autoimmune encephalitis. But the NMD receptor type and the LGI one antibody type, and those should read out as well in about 2026.
